Takeda’s Weekly Oral Proteasome Inhibitor Ixazomib Passes First Pivotal Test
Company plans to submit data from positive TOURMALINE-MM1 study of Velcade follow-on ixazomib in relapsed myeloma to regulators; drug set for 2015 filing.
Company plans to submit data from positive TOURMALINE-MM1 study of Velcade follow-on ixazomib in relapsed myeloma to regulators; drug set for 2015 filing.